B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System

The U.S. Food and Drug Administration (FDA) today approved B. Braun Medical Inc.'s (B. Braun) application for 1g and 2g Ceftazidime for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System.

The availability of 1g and 2g Ceftazidime in the DUPLEX® System will mean faster, safer and accurate administration of Ceftazidime to patients as it can be stored and ready-to-use wherever and whenever it is needed.

"B. Braun is adding 1g and 2g Ceftazidime within the DUPLEX® System to continue to meet customer demands for providing a broad spectrum of intravenous therapies," said Rob Albert, Vice President of Marketing for Pharmaceuticals & Drug Delivery for B. Braun Medical Inc. "The DUPLEX® System ensures sterility and accuracy through a ready-to-use, closed-system design with barcodes – which ultimately contribute to reducing medication errors."

The DUPLEX® Drug Delivery System is a ready-to-use two-compartment, flexible, eco-friendly IV container that stores pre-measured drug and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature and fits in automated medication dispensing systems. DUPLEX® helps healthcare facilities achieve Surgical Care Improvement Project (SCIP), the Joint Commission and USP 797 compliance that improve the practice of healthcare professionals while advancing patient safety.

Healthcare workers administering 1g or 2g Ceftazidime through DUPLEX® simply fold and squeeze the container and shake it to mix the drug and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

Source:

B. Braun Medical Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    B. Braun Melsungen AG. (2019, June 20). B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System. News-Medical. Retrieved on October 24, 2019 from https://www.news-medical.net/news/20110614/B-Braun-receives-FDA-approval-to-use-1g-and-2g-Ceftazidime-in-DUPLEX-Drug-Delivery-System.aspx.

  • MLA

    B. Braun Melsungen AG. "B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System". News-Medical. 24 October 2019. <https://www.news-medical.net/news/20110614/B-Braun-receives-FDA-approval-to-use-1g-and-2g-Ceftazidime-in-DUPLEX-Drug-Delivery-System.aspx>.

  • Chicago

    B. Braun Melsungen AG. "B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System". News-Medical. https://www.news-medical.net/news/20110614/B-Braun-receives-FDA-approval-to-use-1g-and-2g-Ceftazidime-in-DUPLEX-Drug-Delivery-System.aspx. (accessed October 24, 2019).

  • Harvard

    B. Braun Melsungen AG. 2019. B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System. News-Medical, viewed 24 October 2019, https://www.news-medical.net/news/20110614/B-Braun-receives-FDA-approval-to-use-1g-and-2g-Ceftazidime-in-DUPLEX-Drug-Delivery-System.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Aesculap, Osseon partner to distribute VCF treatment devices